// App-Quantinova.ai

4585 : Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.

Researchers

Presenter

  • Jad Chahoud

Principal Investigators

  • Matthew T. Campbell

  • Jianjun Gao

  • Amado J. Zurita

  • Amishi Yogesh Shah

  • Pavlos Msaouel

  • Jeremy Aaron Ross

  • Lianchun Xiao

  • Eric Jonasch

  • Padmanee Sharma

  • Nizar M. Tannir

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • UT Health Science Center at Houston, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved